Orlistat
Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases
Empros Pharma AB · Phase 2 · Completed · Enrollment 200
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo | n/r | n/r | n/r | n/r |
| Orlistat | n/r | n/r | n/r | n/r |
Not shown
- Placebo: endpoint not reported
- Orlistat: endpoint not reported